(0.68%) 5 162.55 points
(0.24%) 38 770 points
(0.77%) 16 280 points
(0.40%) $78.42
(4.76%) $2.24
(1.05%) $2 332.90
(3.57%) $27.64
(-0.06%) $964.75
(-0.08%) $0.928
(-0.43%) $10.83
(-0.15%) $0.796
(-0.13%) $91.33
Quarter results today
(bmo 2024-05-06)
Expected move: +/- 5.85%
Live Chart Being Loaded With Signals
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally...
Stats | |
---|---|
今日成交量 | 216 349 |
平均成交量 | 209 651 |
市值 | 24.38B |
EPS | INR0 ( 2024-01-29 ) |
下一个收益日期 | ( INR0 ) 2024-05-07 |
Last Dividend | INR1.382 ( 2019-02-14 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -23.44 |
ATR14 | INR0.309 (0.28%) |
音量 相关性
Suven Life Sciences 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Suven Life Sciences 相关性 - 货币/商品
Suven Life Sciences 财务报表
Annual | 2022 |
营收: | INR135.39M |
毛利润: | INR129.74M (95.82 %) |
EPS: | INR-6.63 |
FY | 2022 |
营收: | INR135.39M |
毛利润: | INR129.74M (95.82 %) |
EPS: | INR-6.63 |
FY | 2022 |
营收: | INR118.44M |
毛利润: | INR118.44M (100.00 %) |
EPS: | INR-8.86 |
FY | 2021 |
营收: | INR134.78M |
毛利润: | INR134.78M (100.00 %) |
EPS: | INR-5.67 |
Financial Reports:
No articles found.
Suven Life Sciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR0.230 | 2004-09-10 |
Last Dividend | INR1.382 | 2019-02-14 |
Next Dividend | INR0 | N/A |
Payout Date | 2019-02-25 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | INR8.02 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.66 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 1.882 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR1.382 | 0.73% |
2019 | INR1.382 | 0.60% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SBC.NS | Dividend Junior | 2023-09-18 | Insufficient data to determine frequency | 2 | 0.11% | |
MAHLOG.NS | Dividend Junior | 2023-07-13 | Annually | 7 | 0.30% | |
GOACARBON.NS | Dividend Junior | 2023-08-10 | Annually | 18 | 1.38% | |
ATUL.NS | Dividend Junior | 2023-07-13 | Annually | 22 | 0.22% | |
TORNTPHARM.NS | Dividend Junior | 2023-06-23 | Annually | 22 | 0.85% | |
PGHH.NS | Dividend Knight | 2023-11-16 | Semi-Annually | 21 | 0.86% | |
JBMA.NS | Dividend Junior | 2023-09-08 | Annually | 20 | 0.32% | |
DECCANCE.NS | Dividend Junior | 2023-09-22 | Annually | 17 | 0.64% | |
SKFINDIA.NS | Dividend Junior | 2023-06-28 | Annually | 22 | 0.93% | |
METROBRAND.NS | Dividend Junior | 2023-08-31 | Semi-Annually | 3 | 0.18% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -8.91 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | -0.298 | 1.500 | -4.42 | -6.63 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -652.21 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.611 | 2.00 | 9.80 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.611 | 2.00 | 9.69 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | -1.686 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -9.99 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -4.38 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -23.12 | 1.000 | -2.44 | 0 | [1 - 100] |
returnOnEquityTTM | -0.298 | 2.50 | -2.84 | -6.63 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.611 | 2.00 | 9.80 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.611 | 2.00 | 9.80 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.335 | 1.500 | -1.099 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 1.119 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 1.882 |
Suven Life Sciences
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。